From Our Partners
Saturday, July 2, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Single-Dose Anthrax Vaccine Nasal Spray Clinical Trial

by Global Biodefense Staff
August 1, 2016
Anthrax Infection from Bacillus anthracis spores

An anthrax vaccine that could be administered in a single dose is advancing to its first clinical trial with support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

Under a two-year, approximately $14 million contract between ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Altimmune, Inc. of Gaithersburg, Maryland, the company will begin the first clinical trial of its anthrax vaccine NasoShield.

If the vaccine performs well during clinical studies, the contract could be extended an additional three years and up to a total of approximately $120 million to support additional clinical and nonclinical studies and scale-up manufacturing.

See also: FDA Approves New Injection for Inhalational Anthrax

The NasoShield vaccine is unique in that it is administered as an intranasal spray instead of an injection. The vaccine uses a genetically modified Adenovirus 5 as the delivery system. With this system, a non-infectious virus is modified to include genetic material from the anthrax bacteria genome needed to produce an immune response against anthrax.

The only anthrax vaccine currently approved by the U.S. Food and Drug Administration (FDA) requires three doses.

“The sooner people are protected by vaccine after being exposed to anthrax, the more lives we can save,” said Dr. Richard Hatchett, BARDA’s acting director. “A single dose vaccine is ideal to provide fast protection and peace of mind in the critical days after an incident.”

In May 2016, ASPR issued a task order to one of its Centers for Innovation in Advanced Development and Manufacturing (CIADM) to produce the material that will be used for the clinical trial. It marked the first time a CIADM was used to support the development of a candidate vaccine or drug.

See also: Anthrax Capsule Vaccine Shows Promise

In the planned NasoShield clinical studies, the vaccine candidate will be tested for safety and its effectiveness in eliciting an immune response in humans, although participants will not be exposed to anthrax. If development is successful and the product earns FDA licensure, the product would be administered as a nasal spray to protect against infections caused by inhalation anthrax.

In addition to advanced development of NasoShield, BARDA has supported improvement of the currently licensed vaccine, BioThrax, so that fewer doses may be needed to protect against anthrax, as well as other novel vaccines that may require fewer doses, antibiotics and antitoxins. FDA also has approved use of four anthrax-related antibiotics and two anthrax antitoxins developed with BARDA support.

From Our Partners
Tags: AnthraxASPRHHSVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC